Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Introduction

• Org Study ID: J2421
• NTC ID: NCT06376669
• Lead Sponsor Name: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Status: RECRUITING

Conditions

• Renal Cell Carcinoma

Brief Summary

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

Eligibility Criteria

Inclusion Criteria:

1. Age ≥ 18 years
2. Biopsy proven renal cell carcinoma.
3. No clinical or radiographic evidence of metastatic disease.
4. Not a candidate for surgical treatment or local ablative procedures.
5. Subjects are able to undergo either an MRI or administration of contrast agent for CT.

Exclusion Criteria:

1. Prior history of radiation treatment with overlapping fields.
2. Patients with proven metastatic disease.
3. Female subjects who are pregnant or planning to become pregnant during the treatment.